4.88
4.88 (0%)
As of Feb 14, 2025
Corvus Pharmaceuticals, Inc. [CRVS]
Source:
Company Overview
Corvus Pharmaceuticals, Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. We believe our proprietary product candidates have broad potential to address cancers, immune mediated diseases and inflammatory diseases.
| Country | United States |
| Headquarters | burlingame, california |
| Phone Number | ( 650 ) 900-4520 |
| Industry | manufacturing |
| CEO | Richard A. Miller, M.D. |
| Website | clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-27.5 |
| Net Income | $-62.3 |
| Net Cash | $-3.9 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -108.9% |
| Profit as % of Stockholder Equity | -191.3% |
Management Effectiveness
| Return on Equity | -191.3% |
| Return on Assets | -90.4% |
| Turnover Ratio | |
| EBITA | $-27.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $68.9 |
| Total Liabilities | $36.3 |
| Operating Cash Flow | $-25.4 |
| Investing Cash Flow | $-27.5 |
| Financing Cash Flow | $49 |
